Company Overview
| Company Name | KOTAI Biotechnologies, Inc. |
|---|---|
| Representatives | Kazuo Yamashita (CEO) |
| Location |
7F, MinohSenri Bldg.,
3-4-17 Senbahigashi, Minoh Osaka 562-0035, Japan
|
| Phone | 072-737-8903 |
| Date of incorporation | May 30, 2016 |
| Closing month | June |
| Business | Immune AI platform and data analysis |
| Capital | 15,000 thousand Japanese yen |
| Numbers of employee | 20 (As of April 30, 2024) |
Biography
Kazuo Yamashita
- March 2012
- Ph. D. in Physics, Graduate School of Science, Osaka University
- April 2012
- Specially Appointed Researcher, System Immunology Laboratory, Immunology Frontier Research Center (WPI-IFReC), Osaka University
- April 2015
- Specially Appointed Assistant Professor, System Immunology Laboratory, Immunology Frontier Research Center (WPI-IFReC), Osaka University
- May 2016
- Co-founder and CEO, KOTAI Biotechnologies, Inc.
Papers and research themes
Majored in Physics at the Graduate School of Science, Osaka University and involved in theoretical research on novel ordered phases such as Fulde-Ferrell-Larkin-Ovchinnikov (FFLO) and supersolid phases that possibly exist in extremely low temperature regions of photo-excited semiconductors and/or semimetals. The FFLO study was featured as a cover of the journal.
Since 2012, worked in structural bioinformatics and systems biology as a specially appointed researcher and as a specially appointed assistant professor since 2015, at Osaka University Immunology Frontier Research Center, which is known as a world-class immunology research center. Utilized and developed various technologies and methods: in silico modeling, docking, design, molecular dynamics simulations, etc.
In collaboration with Astellas Pharma and the Institute for Protein Research at Osaka University, successfully established a state-of-the-art antibody structure modeling method that was proved in a blind contest, the Second Antibody Modeling Assessment (AMA-II), wherein the team ranked first among six invited groups. Encouraged by the fruitful results in this contest, developed an antibody-modeling server, Kotai Antibody Builder.
During this period, conducted numerous collaborative researches with immunologists, structural biologists, and chemists, and published more than 20 papers in world-renowned journals such as Immunity and Nature structural & molecular biology.
Founded KOTAI Biotechnologies, Inc. in May 2016, and, as a Chief Executive Officer, has been developing and commercializing immune big data analysis pipeline.
This is a unique technology that combines state-of-the-art AI with a deep understanding of Immunology, and has gain recognition: being adopted by NEDO’s FY2017 AI System Joint Development Support Project.
In addition, focused on bioinformatics analysis that combines cutting-edge experimental technologies such as single-cell analysis, and gave many invited talks. Now KOTAI is recognized as a center for Immuno-informatics in Japan.
Management and Advisors
Directors
Chief Executive Officer Kazuo Yamashita
Director Hiroto Nakamura
Director Fumio Nishikaku
Director Satoshi Kishi
Auditor Manabu Fujita
Business Partners
We have established research and development networks with the leading research institutes in Japan.
History
- May, 2016
- Established KOTAI Biotechnologies, Inc. (at Chuo-ku, Osaka-shi, Osaka Prefecture) (Capital: 1,820 thousand Yen)
Started business at Research Institute for Microbial Diseases, Osaka University (at Suita-shi, Osaka Prefecture)
- October, 2016
- Third-party allotment of shares Capital increased to 26,820,000 yen.
- August, 2017
- Third-party allotment of shares Capital increased to 127,320,000 yen.
- February, 2018
- Newly established the office at Building B, Office of Industry-University Co-Creation, Osaka University (Suita-shi, Osaka) with the expansion of the business
- August, 2018
- Osaka Prefectural Government authorized the “Growth Industry Business Plan at the Special Integrated Area of Growth Industry (Suita Campus, Osaka University).”
- February, 2019
- Third-party allotment of shares Capital increased to 252,320,000 yen.
- March, 2019
- Closed the office at Research Institute for Microbial Diseases, Osaka University and integrated into the Building B, Office of Industry-University Co-Creation, Osaka University
- July, 2019
- Relocate the head office from Osaka-shi, Osaka Prefecture to Suita-shi, Osaka Prefecture
- August, 2019
- Moved the laboratory to Building A, Office of Industry-University Co-Creation, Osaka University with the expansion of the business
- March, 2020
- Reduced capital to 10,000,000 yen without compensation
- October, 2020
- Third party allotment of shares Capital increased to 15,000,000 yen
- July, 2023
- Consolidated subsidiary of Sanyo Trading Co., Ltd.
- July, 2024
- Moved headquarter to Minoh, Osaka. Expanded research facilities
Grants and subsidies adopted
- July, 2018
-
Japan Agency for Medical Research and Development (AMED)
“Research project for practical use of infectious diseases”- Study on elucidation and improvement of immune pathology for HIV infection healing
Period 3 years
- July, 2018
-
New Energy and Industrial Technology Development Organization
”AI System Joint Development Support Project 2017 Supplementary Budget”- Development of antibody-enhanced AI based on high throughput experimental data
Period 1 year
- August, 2018
-
The Small and Medium Enterprise Agency
“Subsidy for measures to support small and medium-sized enterprises’ management 2018 (Strategic Basic Technology Advancement Support Project”- Development for identification method of autoantibodies and biomarkers that cause autoimmune diseases
Period 3 years
- November, 2018
-
Japan Agency for Medical Research and Development (AMED)
“Research Project for the Creation of Next-Generation Cancer Medicine”- Clustering and phenotype analysis from T-cell receptor sequences
Period 3 years
- April, 2019
-
Japan Agency for Medical Research and Development (AMED)
“Research project for practical use of infectious diseases, Research Project for Development of Innovative Drugs for Emerging and Re-Emerging Infectious Diseases”- Development of diagnostic methods for congenital and unknown infectious diseases by pathological approach
- Development of basic technology in anticipation of introduction of nasal influenza vaccine
Period 3 years
- October, 2019
-
Japan Agency for Medical Research and Development (AMED)
“Research Project for Practical Application of Innovative Cancer Medicine”- Spatio-temporal analysis of neoantigen-specific T cells by single cell sequence and application to therapeutic targets and biomarkers
Period 3 years
- November, 2019
-
The Small and Medium Enterprise Agency
“2019 Manufacturing, Commerce and Service Advanced Cooperation Promotion Subsidy”- Providing high-precision cell experiment services that achieve large scale and low price
Period 1 year
- April, 2020
-
Japan Agency for Medical Research and Development (AMED)
“Innovative Advanced Research and Development Support Program Step Type (FORCE)”- Elucidation of involvement of neutrophil-activating regulators in the anti-tumor immune response in human lung cancer
Period 2 years
- July, 2020
-
Japan Agency for Medical Research and Development (AMED)
“Emerging and Re-emerging Infectious Diseases Research Infrastructure Creation Project (Research Area Utilizing Overseas Bases)“- Research and development of HIV-1 subtype A/E infections for treatment and prevention
Period 2 years and 9 months
- August, 2020
-
Japan Agency for Medical Research and Development (AMED)
“Program to Develop Countermeasure Technologies against Viral and Other Infectious Diseases”- Development of high-precision and high-performance immune monitoring technologies for SARS-CoV-2 infected patients
Period 6 months
- April, 2021
-
Japan Agency for Medical Research and Development (AMED)
“Research Project for Practical Use of AIDS Prevention”- Study on novel immuno-cell therapies for the radical cure of HIV
Period 3 years
- April, 2021
-
Japan Agency for Medical Research and Development (AMED)
“Research Project for Development Promotion of Innovative Drugs for Emerging and Re-Emerging Infectious Diseases”- Exploratory study on COVID-19 vaccine biomarkers based on immune profiling
Period 1 year
- May, 2021
-
Japan Agency for Medical Research and Development (AMED)
“Research Project for the Creation of Next Generation Cancer Medicine”- Development of a method for single-cell analysis of tumor-infiltrating lymphocytes with genomic abnormalities and elucidation of its clinical significance
Period 1 year
- July, 2021
-
Japan Agency for Medical Research and Development (AMED)
“Japan Program for Infectious Diseases Research and Infrastructure”- Spatial transcriptomics and single cell analysis to study pathogenesis of viral hemorrhagic fever SFTS
Period 3 years
Access
7F, MinohSenri Bldg., 3-4-17 Senbahigashi, Minoh Osaka 562-0035